Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II PK–efficacy/safety study of ganciclovir for cytomegalovirus infection
jRCT1031210407Phase 2Completed
- Sponsor
- Chiba University Hospital
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ganciclovir in cytomegalovirus disease (CMV), sponsored by Chiba University Hospital. Primary endpoint: Relationship between ganciclovir AUC and efficacy. Started Nov 2021; status: completed.
02
Drugs
ganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on jRCT1031210407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031210407.